VivoSim Labs, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
VivoSim Labs, Inc. (VIVS) reported Net Income (Loss) Available to Common Stockholders, Diluted of $7.80 million for the 3-month period ending 2014-06-30, per its 10-Q filed 2014-08-08.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2014-08-08
- VivoSim Labs, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2014-06-30 was $7.80M, a 10.34% decline year-over-year.
- VivoSim Labs, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2013-06-30 was $8.70M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month |
|---|---|
| 2014-06-30 | $7.80M 10-Q · filed 2014-08-08 |
| 2013-06-30 | $8.70M 10-Q · filed 2014-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |